These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 2505269

  • 1. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 4. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 5. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH, Ye G, Wang XW, Jin HS, Zhang YN, Yan ZL.
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [Abstract] [Full Text] [Related]

  • 6. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 7. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 8. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 9. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 10. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 12. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF.
    N Engl J Med; 1991 Oct 24; 325(17):1205-9. PubMed ID: 1922207
    [Abstract] [Full Text] [Related]

  • 14. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 15. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR, Levi d'Ancona CA, Claro JF, Ilari O.
    Arch Esp Urol; 1991 Oct 15; 44(8):1025-8. PubMed ID: 1796850
    [Abstract] [Full Text] [Related]

  • 16. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
    DeBruyne FM, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ.
    Urology; 1988 Mar 15; 31(3 Suppl):20-5. PubMed ID: 3279698
    [Abstract] [Full Text] [Related]

  • 17. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
    Okuno H, Shirahase T, Kihara Y, Arai Y.
    Hinyokika Kiyo; 1989 Sep 15; 35(9):1503-7. PubMed ID: 2816616
    [Abstract] [Full Text] [Related]

  • 18. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
    Leblanc B, Duclos AJ, Bénard F, Valiquette L, Paquin JM, Lapointe S, Mauffette F, Pharand D, Faucher R, Drouin G, Perreault JP.
    Can J Urol; 2000 Feb 15; 7(1):944-8. PubMed ID: 11121250
    [Abstract] [Full Text] [Related]

  • 19. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA, Zhu F, Herr HW.
    BJU Int; 2010 Aug 15; 106(3):357-61. PubMed ID: 20002665
    [Abstract] [Full Text] [Related]

  • 20. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May 15; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.